CN101756990A - Medical composition for losing weight or treating hyperlipidemia - Google Patents
Medical composition for losing weight or treating hyperlipidemia Download PDFInfo
- Publication number
- CN101756990A CN101756990A CN200810175484A CN200810175484A CN101756990A CN 101756990 A CN101756990 A CN 101756990A CN 200810175484 A CN200810175484 A CN 200810175484A CN 200810175484 A CN200810175484 A CN 200810175484A CN 101756990 A CN101756990 A CN 101756990A
- Authority
- CN
- China
- Prior art keywords
- group
- orlistat
- rosuvastain calcium
- compare
- rosuvastatin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a medical composition for losing weight or treating hyperlipidemia, belonging to the field of medicines, and in particular relates to a medical composition containing orlistat or cetilistat and rosuvastatin calcium, wherein the composition is solid preparations such as compressed tablets, dispersible tablets, sustained release tablets, capsules, granules, and the like. In experiments, the medical composition containing the orlistat or the cetilistat and the rosuvastatin calcium is accidentally found to have obvious synergistic effect on the aspects of reducing the serum total cholesterol, the serum triglyceride and the low density lipoprotein cholesterin.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition that is used to lose weight or treats hyperlipidemia, belong to field of medicaments.
Background technology
Along with expanding economy, the improvement of material life condition and dietary structure unreasonable, obesity spreads as pestilence in the developing country that developed country and economy develop rapidly and comes, and sickness rate is soaring year by year, and rejuvenation situation occurs.China obese patient has surpassed 7,000 ten thousand people (not comprising children obesity), accounts for 5.4% of total population.In big cities such as Beijing, Shanghai, adult's overweight of nearly 1/3rd becomes the district occurred frequently of obesity.And over past ten years, the children obesity recall rate increases about 9% every year on average, this means that the quantity of China's Obese children after 10 years will double than now.World Health Organization's official confirmation obesity in 1997 is a kind of disease, and announces to the whole world: " obesity will become the primary health problem in the whole world." fat of causing psychological burden, influencing work and the life; that (obesity is the main hazard factor of many serious diseases: 57% non-insulin-dependent (2 type) diabetes; 36% hyperlipidemia; 30% gallbladder disease; 17% coronary heart disease; 17% hypertension, 14% osteoarthritis, 11% mammary gland, uterus, colorectal cancer or the like) also to have increased incidence rate with obesity-related disease.And slimming medicine is with respect to slimming health product, and curative effect is more definite, treats clearer.Along with people to improving constantly of requiring of quality of life, the market of appetrol also can be increasing.
Sheng Hang fat-reducing Western medicine divides two big classes in the market: nervus centralis drugs with function and non-nervus centralis drugs with function.In China, the former is the most common with fenfluramine and sibutramine, and wherein fenfluramine is because of might the cardiac trigger valve disease, as far back as 1997 just in U.S.'s use that is under an embargo.Sibutramine then can cause elevation of the blood pressure, heart rate is accelerated.Therefore use the medicine of nervus centralis effect to follow the doctor's advice, will regularly detect the fluctuation of heart rate and blood pressure simultaneously, the people that cardiovascular disease and apoplexy history arranged is Ying Shenyong more.Orlistat (Orlistat) is first and is a unique non-nervus centralis medicine, is up-to-date slimming medicine in international popular, and commodity are called orlistat (Xenical), for Roche Holding Ag all, went on the market in the U.S. in 1999.This product is long-acting and potent specificity gastrointestinal tract lipase inhibitor; it by with the harmonization of the stomach small intestinal lumen in the active ser position of gastric lipase and pancreatic lipase form covalent bond and make enzyme deactivation bring into play therapeutical effect; the enzyme of inactivation can not mainly be that triglyceride hydrolysis is absorbable free fatty and monoacylglycerol with the fat in the food.Indigested triglyceride can not be absorbed by health, takes in controlling body weight thereby reduce heat.This medicine need not to absorb the performance drug effect by whole body.Orlistat suppresses fat absorption, therefore may cause steatorrhea, and taking another side effect that orlistat may cause for a long time is fat-soluble avitaminosis.In addition, the up-to-date weight reducing medicine Sai Lisita (Cetilistat) of Alizyme research and development, it is more safer than the appetite suppressant of present use and fat absorption blocker etc., and effect is more obvious.In the II clinical trial phase of just having finished recently, curative effect and the safety of Sai Lisita are confirmed, and its effect is suitable with the similar medicine orlistat of Luo Shi, but the toleration of Sai Lisita is better.
" new medical science " the 36th the 12nd phase of volume of December in 2005 " efficacy analysis of the fat companion of orlistat associating pravastatin treatment dyslipoproteinemia " discloses the fat companion of orlistat associating pravastatin treatment dyslipoproteinemia patient's clinical curative effect analysis, it is divided into orlistat associating pravastatin (observation group at random with 121 routine patients, 61 examples) with two groups of pravastatins (matched group, 60 examples).On the basis of keeping on a diet, the patient of observation group gives orlistat 120mg, every day 3 times, pravastatin 20mg, 1 time every night; The matched group list gives pravastatin 20mg, 1 time every night.Followed up a case by regular visits to 6 months, and detected and the indexs such as body weight, Body Mass Index, waistline and blood fat that compare two groups of patients.Result of the test shows, the fat companion of orlistat associating pravastatin treatment dyslipoproteinemia is a safety and effectively, and it loses weight and the effect of improving dyslipidemia is better than singly using pravastatin.The document does not report whether orlistat and pravastatin use in conjunction have synergism, and the effect that only draws drug combination is better than the pravastatin folk prescription.
Summary of the invention
The obese patient is easy to concurrent hyperlipidemia, do not treat the fat also medicine of hyperlipidemia and be specifically designed in the market, moreover single clothes orlistat can bring certain side effect such as steatorrhea or fat-soluble avitaminosis, in order to address the above problem, by a large amount of experiment sievings, the inventor has proposed orlistat or Sai Lisita and rosuvastain calcium (Rosuvastatin Calcium) drug combination, is used for the treatment of the patient of fat and hyperlipidemia.
Our southern Shandong pharmacy is immediately following slimming medicine research and development forward position, creationary orlistat or Sai Lisita become pharmaceutical composition with the rosuvastain calcium combined preparation, is used for the treatment of the fat also patient of hyperlipidemia.By a large amount of experimental studies, we have finally filtered out rosuvastain calcium from numerous HMG-CoA reductase inhibitors, make that the inventor is beyond thought to be, the use in conjunction of orlistat or Sai Lisita and rosuvastain calcium has shown surprising synergism.
Pharmaceutical composition of the present invention is made up of with rosuvastain calcium and pharmaceutic adjuvant orlistat or Sai Lisita, wherein the weight ratio of orlistat and rosuvastain calcium is 15～75: 1, preferred ratio is 30～75: 1, and further preferred ratio is 36: 1; Wherein the weight ratio of Sai Lisita and rosuvastain calcium is 9～60: 1, and preferred ratio is 15～45: 1, and further preferred ratio is 24: 1.The dosage form of the pharmaceutical preparation of said composition comprises solid preparations such as ordinary tablet, dispersible tablet, slow releasing tablet, capsule, granule, can be according to general formulation method preparation well known in the art.
The present invention from multiple statins, filter out with orlistat or Sai Lisita use in conjunction after have synergistic Rosuvastatin, by to pharmacodynamic study of the present invention, in experiment, be surprised to find that, the use of uniting of orlistat or Sai Lisita and Rosuvastatin is reducing serum total cholesterol, serum triglycerides and low-density lipoprotein cholesterol aspect not only exist the obvious synergistic effect, and use with uniting of orlistat and pravastatin and to compare, lipid-lowering effect is more obvious, aspect the high density lipoprotein increasing cholesterol, apparent in view advantage is arranged also.
Research work by the pharmacology aspect shows, compare with the orlistat of independent application effective dose or Sai Lisita or Rosuvastatin, when with compositions of the present invention, when especially adopting preferred proportioning, have astonishing better effect, toxicity does not increase simultaneously, is reaching under the situation of identical lipid-lowering effect, two class medicines, 5 usefulness greatly reduce the using dosage of every kind of medicine, and this has just significantly reduced the untoward reaction of orlistat or Sai Lisita and the drug risk of Rosuvastatin.
The specific embodiment
The preparation of embodiment 1 compound tablet
Orlistat 150g
Rosuvastain calcium 2g
Microcrystalline Cellulose 45g
Starch 30g
15% starch slurry is an amount of
Magnesium stearate 2.0g
Preparation technology: the common process of pressing tablet prepares promptly.
The preparation of embodiment 2 compound tablet
Orlistat 150g
Rosuvastain calcium 10g
Amylum pregelatinisatum 90g
Lactose 50g
15% starch slurry is an amount of
Micropowder silica gel 1.5g
Preparation technology: the common process of pressing tablet prepares promptly.
Embodiment 3
A, orlistat 120g
Hydroxypropyl emthylcellulose-4M 20g
Microcrystalline Cellulose 10g
The ethanol solution of 8%PVP is an amount of
Magnesium stearate 1.5g
Preparation technology: orlistat is crossed 100 mesh sieves, hydroxypropyl cellulose-4M, microcrystalline Cellulose are crossed 80 mesh sieves, take by weighing the orlistat of recipe quantity and hydroxypropyl cellulose-4M, microcrystalline Cellulose mix homogeneously, adding the 8%PVP ethanol solution granulates in right amount, 60 ℃ of dryings, 16 mesh sieves are put in order dried granule, add the magnesium stearate of recipe quantity in the dried granule.
B, rosuvastain calcium 4g
Sodium carboxymethyl cellulose 40g
Lactose 30g
The 95% alcoholic solution 50g of 6%PVP
Magnesium stearate 2g
Preparation technology: rosuvastain calcium is crossed 100 mesh sieves, sodium carboxymethyl cellulose, lactose are crossed 80 mesh sieves, take by weighing the rosuvastain calcium of recipe quantity and sodium carboxymethyl cellulose, lactose mix homogeneously, 95% alcoholic solution that adds 6%PVP is granulated in right amount, 60 ℃ of dryings, 16 mesh sieves are put in order dried granule, add the magnesium stearate of recipe quantity in the dried granule.
C, with above-mentioned a, two kinds of components of b adopt the bi-layer tablet press punching press promptly to get double-layer tablet.
Embodiment 4
A, Sai Lisita 150g
Celphere 150g
7%PVP solution (solvent is 90% ethanol) is an amount of
Preparation technology: Sai Lisita is crossed 120 mesh sieves, and recipe quantity takes by weighing, and pours in the hopper.Drive the granulating and coating machine, go into wind pressure 0.5bar, 30 ℃ of inlet air temperature, spray gun pressure (CYL) 3bar, atomizing pressure (CAP1) 0.8bar pours celphere into, pelletize, blanking velocity 4rpm, the pump 12% of wriggling, rotary speed 145rpm, spray 7%PVP solution (solvent is 90% ethanol).Pelletize finishes, 50 ℃ of oven dry, discharging.
B, rosuvastain calcium 10g
Celphere 100g
7%PVP solution (solvent is 90% ethanol) is an amount of
Preparation technology: rosuvastain calcium is crossed 120 mesh sieves, and recipe quantity takes by weighing, and pours in the hopper.Drive the granulating and coating machine, go into wind pressure 0.5bar, 30 ℃ of inlet air temperature, CYL3bar, CAP1 0.8bar pours celphere into, pelletize, blanking velocity 4rpm, the pump 6% of wriggling, rotary speed 160rpm, spray 7%PVP solution (solvent is 90% ethanol).Pelletize finishes, 45 ℃ of oven dry, discharging.
C, the piller that a and b are made adopts hard capsule medicine filling machine to be respectively 150mg according to the weight that contains Sai Lisita and rosuvastain calcium in per two capsules and 10mg fills, and gets final product.
The preparation of embodiment 5 compound dispersed tablets
Orlistat 90g
Rosuvastain calcium 2.5g
Cross-linking sodium carboxymethyl cellulose 12g
Microcrystalline Cellulose 160g
Polyvinylpyrrolidone 6g
The 5%PVP60% alcoholic solution is an amount of
Micropowder silica gel 5g
Preparation technology: take by weighing orlistat, rosuvastain calcium by recipe quantity, with the microcrystalline Cellulose is filler, cross-linking sodium carboxymethyl cellulose, polyvinylpyrrolidone are disintegrating agent, 5%PVP 60% alcoholic solution is an adhesive, micropowder silica gel is a fluidizer, use the fluid bed one-step palletizing, tabletting then, promptly.
The preparation of embodiment 6 compound tablet
Sai Lisita 60g
Rosuvastain calcium 1g
Microcrystalline Cellulose 55g
Starch 65g
15% starch slurry is an amount of
Magnesium stearate 2.5g
Preparation technology: the common process of pressing tablet prepares promptly.
The preparation of embodiment 7 compound tablet
Sai Lisita 45g
Rosuvastain calcium 5g
Amylum pregelatinisatum 90g
Lactose 50g
15% starch slurry is an amount of
Micropowder silica gel 1.5g
Preparation technology: the common process of pressing tablet prepares promptly.
The preparation of embodiment 8 compound granular agent
Sai Lisita 90g
Rosuvastain calcium 2g
Starch 180g
Dextrin 50g
Cane sugar powder 60g
80% ethanol is an amount of
Preparation technology: the Sai Lisita, rosuvastain calcium, starch, dextrin, the cane sugar powder mix homogeneously that take by weighing recipe quantity.In addition 80% an amount of ethanol is incorporated in the mixed-powder, mix homogeneously, the system soft material is made wet grain by 18 order nylon mesh, and is dry about 60 ℃, 20 mesh sieve granulate, packing, promptly.
The preparation of embodiment 9 compound dispersed tablets
Orlistat 48g
Rosuvastain calcium 2g
Cross-linking sodium carboxymethyl cellulose 10g
Microcrystalline Cellulose 180g
Polyvinylpyrrolidone 7g
The 5%PVP60% alcoholic solution is an amount of
Micropowder silica gel 4g
Preparation technology: take by weighing Sai Lisita, rosuvastain calcium by recipe quantity, with the microcrystalline Cellulose is filler, cross-linking sodium carboxymethyl cellulose, polyvinylpyrrolidone are disintegrating agent, 5%PVP 60% alcoholic solution is an adhesive, micropowder silica gel is a fluidizer, use the fluid bed one-step palletizing, tabletting then, promptly.
Embodiment 10 compound recipes are to the influence of obesity and hyperlipidemia mice
The preparation of 1 animal model
4 age in week the KM mice, male and female half and half, southern Shandong pharmacy Experimental Animal Center provides, and feeds that (prescription of high lipid food is casein 1kg with high lipid food, L-cysteine 15g, maltodextrin 0.75kg, sucrose 0.35kg, cellulose 0.25kg, soybean oil 0.15kg, Adeps Sus domestica 1.25kg).After raising for 10 weeks, eliminate the mice of body weight, the administration of dividing into groups then less than 60g.
2 grouping and administrations
Modeling success rat is divided into following each group at random according to body weight:
Model group: the normal saline of equal volume
Orlistat group: 18mg/ (kg.d) orlistat
Rosuvastain calcium group: 0.5mg/ (kg.d) rosuvastain calcium
Difficult to understand+general group: 18mg/ (kg.d) orlistat+2.0mg/ (kg.d) pravastatin
Compound recipe low dose group: 9mg/ (kg.d) orlistat+0.25mg/ (kg.d) rosuvastain calcium
Dosage group: 18mg/ (kg.d) orlistat+0.5mg/ (kg.d) rosuvastain calcium in the compound recipe
Compound recipe high dose group: 36mg/ (kg.d) orlistat+1.0mg/ (kg.d) rosuvastain calcium
Every group 8, still feed during the administration with high lipid food, irritate stomach every day three times, irritate stomach at 6:00,14:00,22:00 respectively, continuous 8 weeks.
3 detect index
3.1 body weight determination
The 2nd week began to weigh every 2 weeks after administration, the result shows that since the 4th week, group has been compared significant difference with high group of compound recipe with model group in the compound recipe; From the 6th week, the low group of compound recipe has been compared significant difference with model group, and these show that all each group of compound recipe has fine fat-reducing drug effect.In addition, since the 4th week, each group of compound recipe is compared with the Rosuvastatin group, show significant difference or utmost point significant difference gradually, when the 8th week, each group of compound recipe is compared with the orlistat group has significant difference, and these show that orlistat and Rosuvastatin use in conjunction have good synergism in fat-reducing.In addition, in the 8th when week, in the compound recipe group and high group with difficult to understand+general group compare and have significant difference, this illustrates that orlistat Rosuvastatin compound slimming effect significantly is better than the use in conjunction of orlistat and pravastatin.Experimental result sees table 1 for details.
Each group of table 1 compound recipe is to the influence (unit: g) of mice body weight
* compare P＜0.05 with model group; * and model group compare, P＜0.01;
# and orlistat group compare, P＜0.05; ## and orlistat group compare, P＜0.01;
﹠amp; Compare P＜0.05 with the Rosuvastatin group; ﹠amp; ﹠amp; Compare P＜0.01 with the Rosuvastatin group;
3.2 lipid determination
After administration finishes, detect serum total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), HDL-C (HDL-C), triglyceride (TG).The result shows, the level of T-CHOL, triglyceride, HDL-C and low-density lipoprotein cholesterol has been compared utmost point significant difference with model group, compare with orlistat group or Rosuvastatin group and also to have significant difference or utmost point significant difference, this explanation orlistat and Rosuvastatin use in conjunction have good synergism in blood fat reducing.In addition, no matter be TC, TG, or the level of LDL-C, in the compound recipe group and high group with difficult to understand+general group compare and have significant difference, this illustrates that orlistat Rosuvastatin compound recipe blood fat reducing effect significantly is better than the use in conjunction of orlistat and pravastatin.Experimental result sees table 2 for details.
Each group of table 2 compound recipe is to the influence (mmol/L) of lipid in the mouse blood
* compare P＜0.05 with model group; * and model group compare, P＜0.01;
# and orlistat group compare, P＜0.05; ## and orlistat group compare, P＜0.01;
﹠amp; Compare P＜0.05 with the Rosuvastatin group; ﹠amp; ﹠amp; Compare P＜0.01 with the Rosuvastatin group
Embodiment 11 compound recipes are to the influence of obesity and hyperlipidemia mice
The preparation of 1 animal model
4 age in week the KM mice, male and female half and half, southern Shandong pharmacy Experimental Animal Center provides, and feeds that (prescription of high lipid food is casein 1kg with high lipid food, L-cysteine 15g, maltodextrin 0.75kg, sucrose 0.35kg, cellulose 0.25kg, soybean oil 0.15kg, Adeps Sus domestica 1.25kg).After raising for 10 weeks, eliminate the mice of body weight, the administration of dividing into groups then less than 60g.
2 grouping and administrations
Modeling success rat is divided into following each group at random according to body weight:
Model group: the normal saline of equal volume
Sai Lisita group: 12mg/ (kg.d) Sai Lisita
Rosuvastain calcium group: 0.5mg/ (kg.d) rosuvastain calcium
Difficult to understand+general group: 18mg/ (kg.d) orlistat+3.0mg/ (kg.d) pravastatin
Compound recipe low dose group: 4mg/ (kg.d) Sai Lisita+0.167mg/ (kg.d) rosuvastain calcium
Dosage group: 12mg/ (kg.d) Sai Lisita+0.5mg/ (kg.d) rosuvastain calcium in the compound recipe
Compound recipe high dose group: 36mg/ (kg.d) Sai Lisita+1.5mg/ (kg.d) rosuvastain calcium
Every group 8, still feed during the administration with high lipid food, irritate stomach every day three times, irritate stomach at 6:00,14:00,22:00 respectively, continuous 8 weeks.
3 detect index
3.1 body weight determination
The beginning of the 2nd week was weighed every 2 weeks after the administration, and the result shows, since the 4th week, group and compound recipe height is organized and compared significant difference or utmost point significant difference with model group in the compound recipe; From the 6th week, the low group of compound recipe has been compared significant difference or utmost point significant difference with model group, and these show that all each group of compound recipe has fine fat-reducing drug effect.In addition, since the 4th week, each group of compound recipe is compared with the Rosuvastatin group, show significant difference or utmost point significant difference gradually, when the 8th week, each group of compound recipe is compared with the Sai Lisita group has significant difference or utmost point significant difference, and these show that Sai Lisita and Rosuvastatin use in conjunction have good synergism in fat-reducing.In addition, in the 8th when week, in the compound recipe group and high group with difficult to understand+general group compare and have significant difference, this illustrates that Sai Lisita Rosuvastatin compound slimming effect significantly is better than the use in conjunction of orlistat and pravastatin.Experimental result sees table 3 for details.
Each group of table 3 compound recipe is to the influence (unit: g) of mice body weight
* compare P＜0.05 with model group; * and model group compare, P＜0.01;
# and Sai Lisita group compare P＜0.05; ## and Sai Lisita group compare P＜0.01;
﹠amp; Compare P＜0.05 with the Rosuvastatin group; ﹠amp; ﹠amp; Compare P＜0.01 with the Rosuvastatin group;
3.2 lipid determination
After administration finishes, detect serum total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), HDL-C (HDL-C), triglyceride (TG).The result shows, the level of T-CHOL, triglyceride, HDL-C and low-density lipoprotein cholesterol has been compared utmost point significant difference with model group, compare with Sai Lisita group or Rosuvastatin group and also to have significant difference or utmost point significant difference, this explanation Sai Lisita and Rosuvastatin use in conjunction have good synergism in blood fat reducing.In addition, no matter be TC, TG, or the level of LDL-C, in the compound recipe group and high group with difficult to understand+general group compare and have significant difference, this illustrates that Sai Lisita Rosuvastatin compound recipe blood fat reducing effect significantly is better than the use in conjunction of orlistat and pravastatin.Experimental result sees table 4 for details.
Each group of table 4 compound recipe is to the influence (mmol/L) of lipid in the mouse blood
* compare P＜0.05 with model group; * and model group compare, P＜0.01;
# and Sai Lisita group compare P＜0.05; ## and Sai Lisita group compare P＜0.01;
﹠amp; Compare P＜0.05 with the Rosuvastatin group; ﹠amp; ﹠amp; Compare P＜0.01 with the Rosuvastatin group
With difficult to understand+general group of comparison, P＜0.05;
With difficult to understand+general group of comparison, P＜0.01
Claims (8)
1. a pharmaceutical composition that is used to lose weight or treats hyperlipidemia is characterized in that it contains
1) rosuvastain calcium and
2) orlistat or Sai Lisita.
2. pharmaceutical composition as claimed in claim 1, the weight ratio that it is characterized in that orlistat and rosuvastain calcium is 15～75: 1.
3. pharmaceutical composition as claimed in claim 1, the weight ratio that it is characterized in that orlistat and rosuvastain calcium is 30～75: 1.
4. pharmaceutical composition as claimed in claim 1, the weight ratio that it is characterized in that orlistat and rosuvastain calcium is 36: 1.
5. pharmaceutical composition as claimed in claim 1, the weight ratio that it is characterized in that Sai Lisita and rosuvastain calcium is 9～60: 1.
6. pharmaceutical composition as claimed in claim 1, the weight ratio that it is characterized in that Sai Lisita and rosuvastain calcium is 15～45: 1.
7. pharmaceutical composition as claimed in claim 1, the weight ratio that it is characterized in that Sai Lisita and rosuvastain calcium is 24: 1.
8. as the arbitrary described pharmaceutical composition of claim 1-6, it is characterized in that it is conventional tablet, dispersible tablet, slow releasing tablet, capsule, granule.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101754848A CN101756990B (en) | 2008-11-10 | 2008-11-10 | Medical composition for losing weight or treating hyperlipidemia |
| HK10111888.0A HK1145446A1 (en) | 2008-11-10 | 2010-12-20 | Pharmaceutical composition for losing weight or treating hyperlipidemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101754848A CN101756990B (en) | 2008-11-10 | 2008-11-10 | Medical composition for losing weight or treating hyperlipidemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101756990A true CN101756990A (en) | 2010-06-30 |
| CN101756990B CN101756990B (en) | 2011-05-18 |
Family
ID=42488472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008101754848A Active CN101756990B (en) | 2008-11-10 | 2008-11-10 | Medical composition for losing weight or treating hyperlipidemia |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN101756990B (en) |
| HK (1) | HK1145446A1 (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101889975A (en) * | 2010-07-27 | 2010-11-24 | 北京虹湾医药技术有限公司 | Rosuvastatin calcium sustained-release preparation and preparation method thereof |
| CN103393608A (en) * | 2013-08-13 | 2013-11-20 | 杭州高成生物营养技术有限公司 | Cetilistat pellet and preparation method thereof |
| CN105168158A (en) * | 2015-08-18 | 2015-12-23 | 上海韬鸿化工科技有限公司 | Rosuvastatin calcium dispersible tablet and preparation method thereof |
| CN106955357A (en) * | 2017-05-22 | 2017-07-18 | 张凌 | A kind of compound orlistat composite preparation lost weight for pet and its application |
| CN110314232A (en) * | 2019-08-03 | 2019-10-11 | 黄泳华 | The composition being made of lipase inhibitor and hydroxy-3-methylglutaryl CoA reductase inhibitor |
| CN110357812A (en) * | 2019-08-03 | 2019-10-22 | 黄泳华 | The eutectic compound being made of lipase inhibitor and hydroxy-3-methylglutaryl CoA reductase inhibitor |
-
2008
- 2008-11-10 CN CN2008101754848A patent/CN101756990B/en active Active
-
2010
- 2010-12-20 HK HK10111888.0A patent/HK1145446A1/en unknown
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101889975A (en) * | 2010-07-27 | 2010-11-24 | 北京虹湾医药技术有限公司 | Rosuvastatin calcium sustained-release preparation and preparation method thereof |
| CN103393608A (en) * | 2013-08-13 | 2013-11-20 | 杭州高成生物营养技术有限公司 | Cetilistat pellet and preparation method thereof |
| CN103393608B (en) * | 2013-08-13 | 2015-09-16 | 杭州高成生物营养技术有限公司 | A kind of Cetilistat micropill and preparation method thereof |
| CN105168158A (en) * | 2015-08-18 | 2015-12-23 | 上海韬鸿化工科技有限公司 | Rosuvastatin calcium dispersible tablet and preparation method thereof |
| CN105168158B (en) * | 2015-08-18 | 2018-08-03 | 上海韬鸿化工科技有限公司 | A kind of Rosuvastatin calcium dispersible tablet and preparation method thereof |
| CN106955357A (en) * | 2017-05-22 | 2017-07-18 | 张凌 | A kind of compound orlistat composite preparation lost weight for pet and its application |
| CN106955357B (en) * | 2017-05-22 | 2019-05-07 | 成都导飞科技有限公司 | A kind of compound orlistat composite preparation and its application for pet weight-reducing |
| CN110314232A (en) * | 2019-08-03 | 2019-10-11 | 黄泳华 | The composition being made of lipase inhibitor and hydroxy-3-methylglutaryl CoA reductase inhibitor |
| CN110357812A (en) * | 2019-08-03 | 2019-10-22 | 黄泳华 | The eutectic compound being made of lipase inhibitor and hydroxy-3-methylglutaryl CoA reductase inhibitor |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101756990B (en) | 2011-05-18 |
| HK1145446A1 (en) | 2011-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101756990B (en) | Medical composition for losing weight or treating hyperlipidemia | |
| CN102166338B (en) | Alpinia katsumadai-ginger composite, preparation method thereof and use thereof for preparing toxicity-attenuating and effect-increasing medicine for radiotherapy and chemotherapy of cancer | |
| FI101040B (en) | A process for the preparation of an oral dosage form for the treatment of central dopamine deficiency states | |
| CN102018832B (en) | Weight-reducing composition and preparation method thereof | |
| WO2016029868A1 (en) | Composition and medicinal product for reducing body weight and body fat, and use of said product | |
| CN102091314A (en) | Composition of dried ginger and evodia rutaecarpa, preparation method thereof and application thereof in preparing attenuating synergistic medicament in radiotherapy and chemotherapy of cancer | |
| CN101912110B (en) | Composite with effects of losing weight and lowering blood sugar and blood lipid | |
| CN108542903A (en) | A kind of pharmaceutical composition containing orlistat Yu plant origin lipase inhibitor | |
| CN102917695A (en) | Atazanavir sulfate formulations with improved ph effect | |
| CN102526667B (en) | Loquat leaf/ginger composition for reducing vomiting due to cancer chemotherapy and enhancing effect of cancer chemotherapy, and preparation method thereof | |
| CN102872062A (en) | Medicinal composition for treating or preventing obesity and metabolic syndromes | |
| CN101756993B (en) | Medical composition for losing weight or treating metabolic syndromes | |
| CN106924270B (en) | Orlistat-containing pharmaceutical composition with weight-losing function | |
| CN106349318B (en) | A kind of application of pentacyclic triterpene compound in obesity treating medicine is prepared | |
| CN101884643A (en) | New purpose of pharmaceutical composition containing pioglitazone and heparin or low molecular heparin | |
| CN101757019B (en) | Medical composition for losing weight or treating metabolic syndromes | |
| CN100363017C (en) | Fat-reducing compound preparation | |
| CN103239449A (en) | Ezetimibe, simvastatin and nicotinic acid compound preparation and preparation method of ezetimibe, simvastatin and nicotinic acid compound preparation | |
| CN106038566B (en) | A kind of pharmaceutical composition and its application for curing gastric cancer | |
| CN101590038B (en) | Oral sustained release hypotensive composition | |
| CN104840480B (en) | Metformin/folic acid/vitamin B12New application of pharmaceutical composition | |
| CN1559447A (en) | Extracte of Aspongopus chinensis Dallas and Extraction method therefor medicinal use and preparn. thereof | |
| CN101822833B (en) | Medicament compound containing theophylines and statins | |
| CN109806271B (en) | Pharmaceutical composition for treating allergic dermatitis and preparation thereof | |
| CN100551386C (en) | Dry coating sustained-release tablet of a kind of treatment of arthritis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1145446 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1145446 Country of ref document: HK |